Krabbe disease is a rare, inherited condition that destroys the protective coating around nerve cells in the brain and spinal cord. It affects roughly 0.3 to 2.6 per 100,000 live births, and the most common form appears in the first few months of life. The disease is caused by a missing enzyme that allows a toxic substance to build up in the nervous system, progressively damaging the cells responsible for producing myelin, the insulation that helps nerves transmit signals.
What Happens in the Body
Every cell in your nervous system depends on myelin, a fatty coating that wraps around nerve fibers and allows electrical signals to travel quickly and efficiently. Myelin is produced by two types of cells: oligodendrocytes in the brain and spinal cord, and Schwann cells in the peripheral nerves running through the rest of your body. In Krabbe disease, both cell types are destroyed.
The root cause is a deficiency of an enzyme called galactosylceramidase, or GALC. This enzyme normally breaks down certain fatty molecules that are produced in large quantities during myelination. When GALC is missing or barely functional, one of those molecules, called psychosine, accumulates to toxic levels. Psychosine poisons and kills the very cells that make myelin. As those cells die, the immune system’s cleanup crew in the brain (microglia) becomes overactivated and transforms into large, clustered cells called “globoid cells,” which are the hallmark of the disease and the reason it’s also known as globoid cell leukodystrophy.
The result is progressive demyelination in both the central and peripheral nervous systems. Without myelin, nerve signals slow down or stop entirely, leading to a cascade of neurological problems.
How Krabbe Disease Is Inherited
Krabbe disease follows an autosomal recessive pattern. That means a child must inherit a defective copy of the GALC gene from both parents to develop the condition. Parents who each carry one faulty copy typically have no symptoms themselves. When two carriers have a child, there is a 25% chance with each pregnancy that the child will inherit both defective copies and develop the disease. More than 200 different mutations in the GALC gene have been identified, which partly explains why severity and age of onset vary so widely between patients.
Early Infantile Form: The Most Common
About 80% of all Krabbe disease cases are the early infantile form, with symptoms appearing before six months of age. This is also the most aggressive form. In a study of 117 infants, the most common first symptom was extreme irritability, seen in 56% of patients, with a median onset at 4 months old. Nearly as common were developmental delay or loss of previously gained milestones (46%), feeding or swallowing difficulties (46%), and muscle stiffness or spasticity (43%).
Gastroesophageal reflux affected about a third of infants, and abnormal movements or seizures appeared in roughly 18%. By 8 months of age, 71% of affected infants showed irritability. Swallowing difficulties were reported as early as 3 months and eventually affected 100% of untreated children by around 18 to 23 months. As the disease progresses, children lose the ability to see, hear, move, and swallow. Without treatment, most children with the early infantile form do not survive beyond age two.
Late-Onset Forms
Krabbe disease doesn’t always appear in infancy. It is divided into four subtypes based on when symptoms begin: early infantile (0 to 5 months), late infantile (6 to 36 months), juvenile (3 to 16 years), and adult (older than 16). The later the onset, the slower the progression tends to be.
Children with late-infantile Krabbe disease may develop normally at first, then begin losing motor skills, struggling with walking, or experiencing vision problems during toddlerhood. Juvenile and adult forms are rarer and can look quite different. Adults may initially notice weakness in the legs, difficulty walking, or changes in hand coordination. Some develop cognitive changes or vision problems. Because these symptoms overlap with many other neurological conditions, adult-onset Krabbe disease is often misdiagnosed or diagnosed late.
How It Is Diagnosed
Diagnosis typically begins when a doctor notices worrying neurological symptoms in a child, particularly a combination of irritability, stiffness, and developmental regression. The key diagnostic step is measuring GALC enzyme activity, usually through a blood test. Very low or absent enzyme activity confirms the deficiency. Genetic testing can then identify the specific mutations in the GALC gene.
Brain MRI often shows characteristic abnormalities in the white matter, the areas of the brain rich in myelinated nerve fibers. In infantile cases, these changes can be dramatic and widespread. Nerve conduction studies may also reveal slowed signals in the peripheral nerves, reflecting the damage to Schwann cells.
Krabbe disease is now included on the federal Recommended Uniform Screening Panel (RUSP) for newborns in the United States. Newborn screening tests measure GALC enzyme levels and psychosine concentration in a blood spot taken shortly after birth. This is important because the most effective treatment works best before symptoms appear, making early detection critical.
Stem Cell Transplant: Timing Is Everything
The primary treatment for Krabbe disease is hematopoietic stem cell transplant (HSCT), sometimes called a bone marrow transplant. It is not a cure, but it can significantly extend survival and slow disease progression. The transplant provides the child’s body with donor cells capable of producing functional GALC enzyme.
The catch is timing. The transplant works best when performed before symptoms appear, which is why newborn screening matters so much. In children treated before symptom onset, survival and developmental outcomes improve meaningfully. In one analysis, 70% of untreated patients had died by the time of follow-up, compared to 31% of those who received a transplant. Transplanted patients had roughly a 2.2-fold increase in their chance of surviving beyond each time point after the procedure.
For children who have already developed symptoms, the picture is less encouraging. Existing evidence shows that transplantation after symptom onset does not significantly improve neurodevelopmental outcomes, though it may still offer some survival benefit regardless of the age when symptoms first appeared. The transplant itself carries significant risks, including complications from the conditioning regimen needed to prepare the body for new stem cells.
Gene Therapy in Clinical Trials
A gene therapy called PBKR03 is currently being tested in a Phase 1/2 clinical trial for infants with early infantile Krabbe disease. The therapy uses a viral vector to deliver a working copy of the GALC gene directly into the central nervous system through a single injection at the base of the skull. The trial is enrolling infants between 1 and 9 months of age and testing two dose levels to find the safest and most effective option. If successful, gene therapy could provide a more direct way to restore enzyme production in the brain, potentially addressing some of the limitations of stem cell transplant.